Join the club for FREE to access the whole archive and other member benefits.

Jacob Berlin

CEO at Terray Therapeutics

Jacob is a distinguished inventor at the intersection of nanotechnology and synthetic chemistry. Prior to joining Terray full-time, he ran an NIH-funded lab at City of Hope, where he was an associate professor. He has more than 40 publications, 20 patents and over 11 thousand citations associated with his work. He was named one of the “Rising Stars and Young Nanoarchitects in Materials Science” by the Royal Society of Chemistry and was nominated for the Kabiller Young Investigator Award in Nanoscience and Nanomedicine.

Jacob received his PhD in organometallic chemistry from CalTech where he studied with Nobel Laureate Bob Grubbs. Jacob completed his postdoctoral training at MIT and Rice University focusing on synthetic chemistry and nanotechnology, and received a BA in chemistry from Harvard University (magna cum laude).


Visit website: https://terraytx.com/#team

 jacob-berlin-phd-57a82

 JacobBerlinPhD

See also: Company Terray Therapeutics - Biotechnology company accelerating AI-driven drug discovery

Details last updated 16-Oct-2022

Jacob Berlin News

Terray raised $120 million to advance AI-driven drug discovery

Longevity Technology - 21-Oct-2024

Their partnership with Calico focuses on age-related disease treatments

Read more...

Calico-Terray Therapeutics collaborate to discover and advance therapeutics for diseases of aging

Calico - 12-Oct-2022

Terray’s novel microarray technology, combines wet lab and computer-driven drug development

Read more...